Dermatophagoides farinae

Identification

Name
Dermatophagoides farinae
Accession Number
DB10400
Description

Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.

Type
Biotech
Groups
Approved
Biologic Classification
Allergenics
Allergen Extract
Synonyms
  • American house dust mite
  • American house dust mite extract
  • House dust mite extract, dermatophagoides farinae
  • Insects (whole body), mite dermatophagoides farinae
  • Mite D.F.
  • Mite D.F. (dermatophagoides farinae) standardized

Pharmacology

Indication

Dermatophagoides farinae extract is an allergen extract indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoidesfarinae house dust mites, or skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in adults 18 through 65 years of age

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Treatment with ACTAIR has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation.

Mechanism of action

The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment. Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil catonic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.

Absorption

Allergens in ACTAIR consist mainly of proteins and glycoproteins. There is no direct bioavailability of intact allergens in the blood. Therefore, no pharmacokinetic studies in animals or in humans have been carried out to investigate the pharmacokinetic profile and metabolism of ACTAIR.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Allergenic Extract - Standardized Mite Dermatophagoides FarinaeLiquidIntradermal; SubcutaneousGreer LaboratoriesNot applicableNot applicableCanada flag
Allergenic Extract - Standardized Mite Dermatophagoides FarinaeLiquidIntradermal; SubcutaneousGreer Laboratories1999-03-15Not applicableCanada flag
Allergenic Extract Standardized Mite DFLiquidSubcutaneousHollister Stier, Unit Pharm, Division Of Miles Canada Inc.1992-12-311998-09-25Canada flag
Allergenic Extract Standardized Mite DFLiquidSubcutaneousHollister Stier, Unit Pharm, Division Of Miles Canada Inc.1992-12-311998-09-25Canada flag
Allergenic Extract Standardized Mite Df (10,000 Au/ml)SolutionPercutaneous; SubcutaneousJubilant Hollisterstier Llc1998-01-16Not applicableCanada flag
Allergenic Extract Standardized Mite Df (30,000 Au/ml)SolutionPercutaneous; SubcutaneousJubilant Hollisterstier Llc1997-01-03Not applicableCanada flag
Allergenic Extract, Standardardized Mite, D. FarinaeLiquidIntradermal; Percutaneous; SubcutaneousAlk Abello, Inc.1997-09-15Not applicableCanada flag
Allergenic Extracts - Standardized Mite Dermatophagoides FarinaeLiquidIntradermal; SubcutaneousGreer LaboratoriesNot applicableNot applicableCanada flag
House Dust Mite, Dermatophagoides farinaeInjection10000 [AU]/1mLCutaneous; Intradermal; SubcutaneousAllermed Laboratories, Inc.1986-12-24Not applicableUS flag
Standardized Mite D FarinaeInjection, solution10000 [AU]/1mLPercutaneous; SubcutaneousAllergy Laboratories, Inc.1989-01-25Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AcarizaxDermatophagoides farinae (6 unit) + Dermatophagoides pteronyssinus (6 unit)TabletSublingualAlk Abello A/S2017-11-06Not applicableCanada flag
Allergen Pack Dermatophagoides FarinaeDermatophagoides farinae (15000 [AU]/1mL) + Sodium chloride (0.9 g/1mL)KitIntradermal; SubcutaneousAlvix Laboratories2015-07-212018-03-08US flag
Allergenic Extract - Standardized Mite MixDermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)LiquidIntradermal; SubcutaneousGreer Laboratories2002-08-20Not applicableCanada flag
Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)Dermatophagoides farinae (15000 unit) + Dermatophagoides pteronyssinus (15000 unit)SolutionPercutaneous; SubcutaneousJubilant Hollisterstier Llc1998-01-16Not applicableCanada flag
Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml)Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)SolutionPercutaneous; SubcutaneousJubilant Hollisterstier Llc1998-01-16Not applicableCanada flag
Allergenic Extract Standardized Mite MixDermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)LiquidSubcutaneousHollister Stier, Unit Pharm, Division Of Miles Canada Inc.1992-12-311998-09-25Canada flag
Allergenic Extract Standardized Mite MixDermatophagoides farinae (15000 unit) + Dermatophagoides pteronyssinus (15000 unit)LiquidSubcutaneousHollister Stier, Unit Pharm, Division Of Miles Canada Inc.1992-12-311998-09-23Canada flag
Allergenic Extract, Standardized Mite MixedDermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)LiquidIntradermal; Percutaneous; SubcutaneousAlk Abello, Inc.2006-02-28Not applicableCanada flag
Mixture of Standardized MitesDermatophagoides farinae (5000 [AU]/1mL) + Dermatophagoides pteronyssinus (5000 [AU]/1mL)Injection, solutionIntradermal; SubcutaneousAntigen Laboratories, Inc.1991-10-22Not applicableUS flag
OdactraDermatophagoides farinae (6 [arb'U]/1) + Dermatophagoides pteronyssinus (6 [arb'U]/1)TabletSublingualALK-Abello A S2018-01-01Not applicableUS flag

Categories

ATC Codes
V01AA03 — House dust mites
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
PR9U2YPF3Q
CAS number
Not Available

References

General References
  1. Liu L, Guo D, Liang Q, Ding S, Wu B, Zhang L, Li Q: The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy. 2015 Apr;45(4):815-22. doi: 10.1111/cea.12417. [PubMed:25258013]
  2. Eremina OIu, Stepanova GN: [The mechanism of action of permethrin on house dust mites]. Izv Akad Nauk Ser Biol. 1995 Jan-Feb;(1):72-9. [PubMed:7894317]
  3. Mauro M, Boni E, Makri E, Incorvaia C: Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opin Drug Metab Toxicol. 2015;11(12):1937-43. doi: 10.1517/17425255.2015.1113255. Epub 2015 Nov 13. [PubMed:26565665]
  4. Drug information [Link]
PubChem Substance
347910575
RxNav
1116977
Wikipedia
Dermatophagoides_farinae
AHFS Codes
  • 92:05.00* — Allergenic Extracts

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentAllergic Asthma Due to Dermatophagoides Pteronyssinus1
3CompletedTreatmentRespiratory Hypersensitivity1
3CompletedTreatmentRhinoconjunctivitis1
3RecruitingTreatmentAllergic Asthma Due to Dermatophagoides Farinae / Allergic Asthma Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite1
3RecruitingTreatmentAllergic Rhinitis (AR) / Rhinoconjunctivitis, Allergic1
3RecruitingTreatmentAllergic Rhinitis Due to Dermatophagoides Farinae / Allergic Rhinitis Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite1
3RecruitingTreatmentRhinoconjunctivitis, Allergic1
Not AvailableRecruitingNot AvailableAllergic Asthma Due to Dermatophagoides Farinae / Allergic Asthma Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderOral12 SQ-HDM
Tablet, orally disintegratingOral6 SQ-HDM
Injection, solutionSubcutaneous1000 TU/ml
Tablet, orally disintegratingOral12 U
KitIntradermal; Subcutaneous
SolutionPercutaneous; Subcutaneous
LiquidSubcutaneous
SolutionPercutaneous; Subcutaneous
LiquidSubcutaneous
LiquidIntradermal; Percutaneous; Subcutaneous
LiquidIntradermal; Percutaneous; Subcutaneous
Injection, suspensionSubcutaneous100 SQ-U/ml
Injection, suspensionSubcutaneous2.5 ml
SolutionSublingual300 IR (U/Reactivity)
InjectionCutaneous; Intradermal; Subcutaneous10000 [AU]/1mL
TabletSublingual
TabletSublingual50 SRU
Injection, solutionPercutaneous; Subcutaneous10000 [AU]/1mL
Injection, solutionSubcutaneous5000 [AU]/1mL
SolutionPercutaneous10000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous10000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous30000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous5000 [AU]/1mL
Injection, solutionIntradermal; Subcutaneous10000 [AU]/1mL
ConcentrateIntradermal; Percutaneous; Subcutaneous
Injection, solutionSubcutaneous
LiquidIntradermal; Subcutaneous
Injection, solutionIntradermal; Subcutaneous3000 [AU]/1mL
Injection, solutionIntradermal; Subcutaneous5000 [AU]/1mL
Injection, solutionSubcutaneous10000 [AU]/1mL
Injection, solutionIntradermal30 [AU]/1mL
Injection, solutionIntradermal300 [AU]/1mL
Injection, solutionPercutaneous; Subcutaneous30000 [AU]/1mL
LiquidIntradermal; Subcutaneous
Injection, solutionPercutaneous
Injection, solutionIntradermal; Subcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:03 / Updated on January 25, 2021 22:38